Scarica l'app Stockscreener
0.0001
51.40%
-0.111
Vaxxinity Inc Borsa (VAXX) Ultime notizie
Victory Capital (NASDAQ:VCTR) Hits New 12-Month High at $56.29 - MarketBeat
IPO Roundup: Guardian Pharmacy Services, BKV Corp and more (NYSEARCA:IPO) - Seeking Alpha
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Victory Capital Management Inc. Makes New Investment in MediaAlpha, Inc. (NYSE:MAX) - Defense World
Zhengye Biotechnology Holding Limited Plans $7 Million IPO for September 27th (ZYBT) - Defense World
Victory Capital Management Inc. Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Broker tips: Volution, UK supermarkets - ShareCast
Vaxcyte president and CFO sells over $900k in stock - Investing.com
Wave Life Sciences gains as B. Riley issues buy on RNS editing tech - MSN
Waltham biotech joins IPO buzz, plans to list on Nasdaq - The Business Journals
Vaxxinity (OTC:VAXX) Stock Quotes, Forecast and News Summary - Benzinga
Vaxxinity (NASDAQ:VAXX) Stock Price Up 13.2% - Defense World
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine - GlobeNewswire
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine - The Bakersfield Californian
Vaxxinity (NASDAQ:VAXX) Trading 11.4% Higher - Defense World
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
Vaxxinity (VAXX) Stock Forecast and Price Target 2024 - MarketBeat
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
Why Vaxxinity (VAXX) Shares Are Volatile Today - Benzinga
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - Yahoo Finance
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - Yahoo Finance
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology
Vaxxinity Announces Positive Target Engagement Data from - GlobeNewswire
Private companies in Vaxxinity, Inc. (NASDAQ:VAXX) are its biggest bettors, and their bets paid off as stock gained 22% last week - Simply Wall St
Vaxxinity Faces Nasdaq Delisting Over Share Price - TipRanks
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - GlobeNewswire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - Yahoo Finance
Vaxxinity is brewing up meds for a spacefaring future - PharmaVoice
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases - Yahoo Finance
Vaxxinity Wants to Bring Accessible Vaccines for Chronic Illness to Market - Cheddar
Vaxxinity, UCF to develop special new vaccines for deep-space astronauts - The Business Journals
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference - GlobeNewswire
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX) - Yahoo Finance
Fast-Tracked Alzheimer's Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient
Vaxxinity publishes positive results in Alzheimer’s trial - Longevity.Technology
Vaxxinity Alzheimer’s treatment shows promising results in early trial - BioPharma-Reporter.com
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease - Yahoo Finance
Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director - Yahoo Finance
Vaxxinity Appoints Peter Powchik, M.D., to EVP, Global Scientific Director - citybiz
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients - GlobeNewswire
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease - South Florida Hospital News
Vaxxinity celebrates trial success in early Parkinson's therapy - Clinical Trials Arena
Positive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s Disease - Yahoo Finance
Vaxxinity shares update about potential vaccine UB-312 - Parkinson's News Today
VXX-301, a tau vaccine with optimized properties - BioWorld Online
Vaxxinity to Present at World Vaccine Congress, American - GlobeNewswire
Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer's treatment - Fierce Biotech
Clinical Trial of Investigational Vaccine to Treat LDL Cholesterol Underway - Diagnostic and Interventional Cardiology
Vaxxinity Joins TransCelerate Research and Development Consortium - Yahoo Finance
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia - Yahoo Finance
Vaxxinity moves HQ, jobs to Florida's Space Coast from Texas - The Business Journals
Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida - Yahoo Finance
Vaxxinity eyes global COVID-19 vaccine market with ‘next-gen’ booster - PharmaVoice
Vaxxinity Stock: Potential Strong Upsides Ahead (NASDAQ:VAXX) - Seeking Alpha
Estimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX) - Yahoo Lifestyle UK
Pursuing A "Biologic Revolution" With Vaxxinity's Mei Mei Hu - BioProcess Online
Vaxxinity's Phase III Covid-19 booster trial meets endpoints - Clinical Trials Arena
Vaxxinity says COVID shot outperformed Astra and Sinopharm shots as booster (NASDAQ:VAXX) - Seeking Alpha
Vaxxinity, Inc. (NASDAQ:VAXX) stock most popular amongst private companies who own 48%, while individual investors hold 21% - Yahoo Canada Finance
Vaxxinity concludes subject enrolment in Phase III Covid-19 vaccine trial - Clinical Trials Arena
Multiple insiders bought Vaxxinity, Inc. (NASDAQ:VAXX) stock earlier this year, a positive sign for shareholders - Yahoo Finance
Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator - Seeking Alpha
Vaxxinity Inc (NASDAQ: VAXX) Recently Issued an Update of Its STL 919 Study To its Shareholders - BP Journal
Vaxxinity down 9% after massive 84% rise in last trading session following insider buys - Seeking Alpha
Dallas-based Vaxxinity begins Phase 3 trial for COVID-19 booster vaccine - The Dallas Morning News
CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants - CEPI
Vaxxinity slips further as post-IPO quiet period expires (NASDAQ:VAXX) - Seeking Alpha
Vaxxinity Has a Rough Public Debut - The Motley Fool
Vaxxinity (VAXX) Stock Price, News & Analysis - MarketBeat
Dallas-based Vaxxinity to go public Thursday with a valuation of about $2 billion - The Dallas Morning News
Dallas-Based Vaxxinity Prepares for $100M IPO; Aims to Turn Immune Systems Into 'Antibody Factories' - dallasinnovates.com
1.35%
0.87%
Capitalizzazione:
|
Volume (24 ore):